ClinicalTrials.gg
CompletedNCT04677504Updated Jul 3, 2024Results posted

A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer

A Phase 2 interventional study of Atezolizumab and Bevacizumab in Biliary Tract Cancer, sponsored by Hoffmann-La Roche. Completed at 49 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-03.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 155 studies in Biliary Tract Neoplasms with a site in United States — 48 open to participants now, 67 under way, 9 of them phase 3. Biliary Tract Neoplasms · United States.

Enrollment
45th of 140
162 · median 75
Started
2021
with 8 others
Phase 2
51 of 155
9 open now
Registered
86th of 155
by date

Among the 155 studies in Biliary Tract Neoplasms with a site in United States, this one is the 45th largest by enrollment of the 140 interventional ones that give a count, is one of 9 that started in 2021, is one of 51 in phase 2, and was the 86th registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

48 of the 155 studies in Biliary Tract Neoplasms with a site in United States are open now. Recruiting first, the newest first:

43 more — sign in →

All 48 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 140 Biliary Tract Neoplasms studies recruiting now, 80 (57%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies in Biliary Tract Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of atezolizumab with bevacizumab in combination with cisplatin and gemcitabine(CisGem), compared with atezolizumab in combination with CisGem, in participants with advanced biliary tract cancer (BTC) who have not received prior systemic therapy. Treatment will consist of a chemotherapy combination phase followed by a cancer immunotherapy (CIT)/placebo phase.

03

Conditions studied

  • Biliary Tract Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Considered to be eligible to receive platinum-based chemotherapy, in the investigator's judgment
  • Documentation of recurrent/ or locally advanced unresectable disease based on computed tomography (CT) or magnetic resonance imaging (MRI) scans
  • or cytologically confirmed diagnosis of iCCA, eCCA, or GBC
  • No prior systemic therapy for advanced BTC
  • At least one measurable untreated lesion (per v1.1)
  • Adequate biliary drainage with no evidence of ongoing infection
  • Performance Status of 0 or 1
  • of > 3 months
  • Adequate hematologic and end-organ function
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use methods, and agreement to refrain from donating eggs
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm

Exclusion criteria

Exclusion Criteria:

  • Recurrent disease \<=6 months after curative surgery or \<= 6 months after the completion of therapy
  • Prior local regional therapy such as radioembolization
  • Combined or mixed hepatocellular/cholangiocarcinoma
  • hepatic encephalopathy within the 12 months prior to Day 1 of Cycle 1
  • National Cancer Institute Common Terminoogy Criteria for Adverse Events Grade >= 2 peripheral neuropathy
  • Prior bleeding event due to untreated or incompletely treated esophageal and/or gastric varices within 6 months prior to Day 1 of Cycle 1
  • Pregnant or breastfeeding, or intending to become pregnant during the study or within 5 months after the final dose of atezolizumab or within 6 months after the final dose of bevacizumab, cisplatin or gemcitabine
  • Active or history of disease or immune deficiency
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography scan
  • History of other than BTC within 5 years prior to screening, with the exception of malignancies with a negligible risk of or death
  • Symptomatic, untreated, or actively progressing
  • For patients with lung metastases, if one of the following criteria applies: Large, centrally located pulmonary metastases; Clear tumor infiltration into the thoracic great vessels seen on imaging; Clear cavitation of pulmonary lesions seen on imaging
  • Active tuberculosis
  • Co-infection with and
  • Treatment with systemic immunostimulatory agents or medication
  • Inadequately controlled arterial hypertension
  • History of hypertensive crisis or hypertensive encephalopathy
  • Significant vascular disease
  • Evidence of bleeding diathesis or significant coagulopathy
  • Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture
  • Chronic daily treatment with a non-steroidal anti-inflammatory drug (NSAID)
  • Preexisting renal impairment, myelosuppression, or hearing impairment
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
162 participants (actual)

Study arms

  • Experimental
    Arm A: Atezo+Bev+CisGem, followed by Atezo+Bev

    Participants will receive atezolizumab intravenously on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status. Participants will receive bevacizumab intravenously on Day 1 of each 21-day cycle. Participants will receive cisplatin intravenously followed by gemcitabine on Days 1 and 8 of each 21-day cycle for Cycles 1-8.

    Drug: Atezolizumab · Drug: Bevacizumab · Drug: Cisplatin · Drug: Gemcitabine

  • Active comparator
    Arm B: Atezo+PBO+CisGem, followed by Atezo+PBO

    Participants will receive atezolizumab intravenously on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status. Participants will receive placebo matching bevacizumab intravenously on Day 1 of each 21-day cycle. Participants will receive cisplatin intravenously followed by gemcitabine on Days 1 and 8 of each 21-day cycle for Cycles 1-8.

    Drug: Atezolizumab · Other: Placebo · Drug: Cisplatin · Drug: Gemcitabine

Interventions

  • Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.

    Also known as: Tecentriq

  • Bevacizumab will be administered at a dose of 15 mg/kg intravenously on Day 1 of each 21-day cycle after atezolizumab.

    Also known as: Avastin

  • OtherPlacebo

    Placebo matching bevacizumab will be administered intravenously on Day 1 of each 21-day cycle after atezolizumab.

  • Cisplatin will be administered intravenously at a dose of 25 mg/m\^2 on Days 1 and 8 of each 21-day cycle for Cycles 1-8.

  • Gemcitabine will be administered intravenously at a dose of 1000 mg/m\^2 on Days 1 and 8 of each 21-day cycle for Cycles 1-8.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the time from randomization to the first occurrence of disease progression as determined by the investigator according to RECIST v1.1 or death from any cause (whichever occurs first)

    Time frame: Randomization to the first occurrence of disease progression as determined by the investigator according to RECIST v1.1 or death from any cause (whichever occurs first)(up to approximately 14 months)

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from randomization to death from any cause.

    Time frame: Randomization to death from any cause (up to approximately 23 months)

  2. Confirmed Objective Response Rate (ORR)

    Confirmed ORR is defined as the proportion of participants with Complete Response (CR) or Partial Response (PR) on two consecutive occasions \>=4 weeks apart, as determined by the investigator according to RECIST v1.1.

    Time frame: Randomization up to approximately 14 months

  3. Duration of Response (DOR)

    DOR is defined as the time from the first occurrence of a confirmed objective response to disease progression as determined by the investigator according to RECIST v1.1 or death from any cause (whichever occurs first).

    Time frame: First occurrence of a confirmed objective response to disease progression as determined by the investigator according to RECIST v1.1 or death from any cause (whichever occurs first)(up to approximately 14 months)

  4. Disease Control Rate (DCR)

    DCR is defined as the proportion of participants with a CR or a PR on two consecutive occasions \>= 4 weeks apart or SD with a minimum duration of 9weeks, as determined by the investigator according to RECIST v1.1

    Time frame: Randomization up to approximately 14 months

  5. Time to Confirmed Deterioration (TTCD)

    TTCD in patient-reported physical functioning, role functioning, and quality of life, as measured by the respective scales of the EORTC QLQ-C30 and/or EORTC IL77, and defined as the time from randomization to the first clinically meaningful deterioration that is either maintained for two consecutive assessments or followed by death from any cause within 3 weeks.

    Time frame: Randomization to the first clinically meaningful deterioration (up to approximately 14 months)

  6. Percentage of Participants With at Least One Adverse Event

    Percentage of participants with at least one adverse event.

    Time frame: Treatment start up to approximately 30 months.

  7. Serum Concentration of Atezolizumab

    Serum concentration of atezolizumab at specified timepoints.

    Time frame: Pre-Dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16, and Post Dose Day 1 of Cycle 1 (cycle length=21 days)

  8. Prevalence of ADAs to Atezolizumab

    Time frame: Baseline

  9. Incidence of ADAs to Atezolizumab

    Time frame: At pre-defined intervals from administration of study drug up to approximately 14 months

07

Results

Posted Jun 29, 2023

Participant flow

The study is considered "Completed" because all pre-planned study activities and analyses have been performed. Participants are ongoing treatment on a roll over study.

Participant flow — Overall Study
MilestoneArm B: Atezo+PBO+CisGem (Cycle*1-8), Followed by Atezo+PBO (Cycle*9 and Beyond)Arm A: Atezo+Bev+CisGem (Cycle*1-8), Followed by Atezo+Bev (Cycle*9 and Beyond)
Started8379
Completed00
Not completed8379
Withdrew: Death5149
Withdrew: Progressive disease10
Withdrew: Symptomatic deterioration10
Withdrew: Withdrawal by subject25
Withdrew: Study terminated by sponsor2824
Withdrew: Adverse event01

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS is defined as the time from randomization to the first occurrence of disease progression as determined by the investigator according to RECIST v1.1 or death from any cause (whichever occurs first)

Time frame:
Randomization to the first occurrence of disease progression as determined by the investigator according to RECIST v1.1 or death from any cause (whichever occurs first)(up to approximately 14 months)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsArm B: Atezo+PBO+CisGem (Cycle*1-8), Followed by Atezo+PBO (Cycle*9 and Beyond)Arm A: Atezo+Bev+CisGem (Cycle*1-8), Followed by Atezo+Bev (Cycle*9 and Beyond)
Progression Free Survival (PFS)7.92 (6.18 to 8.41)8.35 (6.83 to 9.96)
Statistical analysis
  • Arm B: Atezo+PBO+CisGem (Cycle*1-8), Followed by Atezo+PBO (Cycle*9 and Beyond) vs Arm A: Atezo+Bev+CisGem (Cycle*1-8), Followed by Atezo+Bev (Cycle*9 and Beyond) · Regression, Cox · Hazard ratio (hr): 0.76 · 95% CI 0.51 to 1.14
SecondaryOverall Survival (OS)

OS is defined as the time from randomization to death from any cause.

Time frame:
Randomization to death from any cause (up to approximately 23 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsArm B: Atezo+PBO+CisGem (Cycle*1-8), Followed by Atezo+PBO (Cycle*9 and Beyond)Arm A: Atezo+Bev+CisGem (Cycle*1-8), Followed by Atezo+Bev (Cycle*9 and Beyond)
Overall Survival (OS)14.59 (11.17 to NA)14.85 (11.63 to 17.97)
Statistical analysis
  • Arm B: Atezo+PBO+CisGem (Cycle*1-8), Followed by Atezo+PBO (Cycle*9 and Beyond) vs Arm A: Atezo+Bev+CisGem (Cycle*1-8), Followed by Atezo+Bev (Cycle*9 and Beyond) · Log Rank · p = 0.8857 · Hazard ratio (hr): 0.97 · 95% CI 0.64 to 1.47
SecondaryConfirmed Objective Response Rate (ORR)

Confirmed ORR is defined as the proportion of participants with Complete Response (CR) or Partial Response (PR) on two consecutive occasions \>=4 weeks apart, as determined by the investigator according to RECIST v1.1.

Time frame:
Randomization up to approximately 14 months
Reported as:
Number · Percentage of participants
Confirmed Objective Response Rate (ORR)
Percentage of participantsArm B: Atezo+PBO+CisGem (Cycle*1-8), Followed by Atezo+PBO (Cycle*9 and Beyond)Arm A: Atezo+Bev+CisGem (Cycle*1-8), Followed by Atezo+Bev (Cycle*9 and Beyond)
Confirmed Objective Response Rate (ORR)25.324.1
SecondaryDuration of Response (DOR)

DOR is defined as the time from the first occurrence of a confirmed objective response to disease progression as determined by the investigator according to RECIST v1.1 or death from any cause (whichever occurs first).

Time frame:
First occurrence of a confirmed objective response to disease progression as determined by the investigator according to RECIST v1.1 or death from any cause (whichever occurs first)(up to approximately 14 months)
Reported as:
Median · Months
Duration of Response (DOR)
MonthsArm B: Atezo+PBO+CisGem (Cycle*1-8), Followed by Atezo+PBO (Cycle*9 and Beyond)Arm A: Atezo+Bev+CisGem (Cycle*1-8), Followed by Atezo+Bev (Cycle*9 and Beyond)
Duration of Response (DOR)5.78 (4.27 to 6.70)NA (6.44 to NA)
SecondaryDisease Control Rate (DCR)

DCR is defined as the proportion of participants with a CR or a PR on two consecutive occasions \>= 4 weeks apart or SD with a minimum duration of 9weeks, as determined by the investigator according to RECIST v1.1

Time frame:
Randomization up to approximately 14 months
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR)
Percentage of participantsArm B: Atezo+PBO+CisGem (Cycle*1-8), Followed by Atezo+PBO (Cycle*9 and Beyond)Arm A: Atezo+Bev+CisGem (Cycle*1-8), Followed by Atezo+Bev (Cycle*9 and Beyond)
Disease Control Rate (DCR)75.978.5
SecondaryTime to Confirmed Deterioration (TTCD)

TTCD in patient-reported physical functioning, role functioning, and quality of life, as measured by the respective scales of the EORTC QLQ-C30 and/or EORTC IL77, and defined as the time from randomization to the first clinically meaningful deterioration that is either maintained for two consecutive assessments or followed by death from any cause within 3 weeks.

Time frame:
Randomization to the first clinically meaningful deterioration (up to approximately 14 months)
Reported as:
Median · Months
Time to Confirmed Deterioration (TTCD)
MonthsArm B: Atezo+PBO+CisGem (Cycle*1-8), Followed by Atezo+PBO (Cycle*9 and Beyond)Arm A: Atezo+Bev+CisGem (Cycle*1-8), Followed by Atezo+Bev (Cycle*9 and Beyond)
Quality of Life6.28 (3.06 to NA)2.79 (1.58 to 5.32)
Physical Function Scale3.29 (1.87 to 10.58)6.21 (4.63 to NA)
Role Function Scale3.52 (2.20 to 8.51)4.24 (2.10 to 6.28)
Statistical analysis
  • Arm B: Atezo+PBO+CisGem (Cycle*1-8), Followed by Atezo+PBO (Cycle*9 and Beyond) vs Arm A: Atezo+Bev+CisGem (Cycle*1-8), Followed by Atezo+Bev (Cycle*9 and Beyond) · Regression, Cox · Hazard ratio (hr): 1.56 · 95% CI 0.93 to 2.63
  • Arm B: Atezo+PBO+CisGem (Cycle*1-8), Followed by Atezo+PBO (Cycle*9 and Beyond) vs Arm A: Atezo+Bev+CisGem (Cycle*1-8), Followed by Atezo+Bev (Cycle*9 and Beyond) · Regression, Cox · Hazard ratio (hr): 0.81 · 95% CI 0.48 to 1.36
  • Arm B: Atezo+PBO+CisGem (Cycle*1-8), Followed by Atezo+PBO (Cycle*9 and Beyond) vs Arm A: Atezo+Bev+CisGem (Cycle*1-8), Followed by Atezo+Bev (Cycle*9 and Beyond) · Regression, Cox · Hazard ratio (hr): 1.12 · 95% CI 0.68 to 1.85
SecondaryPercentage of Participants With at Least One Adverse Event

Percentage of participants with at least one adverse event.

Time frame:
Treatment start up to approximately 30 months.
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least One Adverse Event
Percentage of participantsArm B: Atezo+PBO+CisGem (Cycle*1-8), Followed by Atezo+PBO (Cycle*9 and Beyond)Arm A: Atezo+Bev+CisGem (Cycle*1-8), Followed by Atezo+Bev (Cycle*9 and Beyond)
Percentage of Participants With at Least One Adverse Event100100
SecondarySerum Concentration of Atezolizumab

Serum concentration of atezolizumab at specified timepoints.

Time frame:
Pre-Dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16, and Post Dose Day 1 of Cycle 1 (cycle length=21 days)
Reported as:
Mean · μg/ mL
Serum Concentration of Atezolizumab
μg/ mLArm A: Atezo+Bev+CisGem (Cycle*1-8), Followed by Atezo+Bev (Cycle*9 and Beyond)Arm B: Atezo+PBO+CisGem (Cycle*1-8), Followed by Atezo+PBO (Cycle*9 and Beyond)
Cycle 1 Day 1 Pre-DoseNA ± NANA ± NA
Cycle 1 Day 1 Post Dose411 ± 73.8416 ± 173
Cycle 2 Day 1 Pre-Dose79.4 ± 46.185.0 ± 71.7
Cycle 3 Day 1 Pre-Dose118 ± 41.4129 ± 83.5
Cycle 4 Day 1 Pre-Dose155 ± 50.6153 ± 74.8
Cycle 8 Day 1 Pre-Dose200 ± 100224 ± 126
Cycle 12 Day 1 Pre-Dose210 ± 76.4223 ± 103
Cycle 16 Day 1 Pre-Dose174 ± 64.9230 ± 71.6
SecondaryPrevalence of ADAs to Atezolizumab
Time frame:
Baseline

No measurements were reported for this outcome.

SecondaryIncidence of ADAs to Atezolizumab
Time frame:
At pre-defined intervals from administration of study drug up to approximately 14 months

No measurements were reported for this outcome.

Adverse events

Collected over From the first study drug until the data cut-off on 25 August 2023 (up to approximately 30 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm B: Atezo+PBO+CisGem (Cycle*1-8), Followed by Atezo+PBO (Cycle*9 and Beyond)51/83 (61.4%)43/81 (53.1%)81/81 (100%)
Arm A: Atezo+Bev+CisGem (Cycle*1-8), Followed by Atezo+Bev (Cycle*9 and Beyond)49/79 (62%)36/78 (46.2%)77/78 (98.7%)
Most frequent serious events
Showing 10 of 98
Most frequent serious events
EventArm B: Atezo+PBO+CisGem (Cycle*1-8), Followed by Atezo+PBO (Cycle*9 and Beyond)Arm A: Atezo+Bev+CisGem (Cycle*1-8), Followed by Atezo+Bev (Cycle*9 and Beyond)
AnaemiaBlood and lymphatic system disorders6/811/78
PyrexiaGeneral disorders5/813/78
CholangitisHepatobiliary disorders5/812/78
Acute kidney injuryRenal and urinary disorders1/813/78
Biliary obstructionHepatobiliary disorders3/810/78
Jaundice cholestaticHepatobiliary disorders3/810/78
Febrile neutropeniaBlood and lymphatic system disorders0/812/78
NeutropeniaBlood and lymphatic system disorders2/812/78
ThrombocytopeniaBlood and lymphatic system disorders2/812/78
HaematemesisGastrointestinal disorders0/812/78
Most frequent other events
Showing 10 of 55
Most frequent other events
EventArm B: Atezo+PBO+CisGem (Cycle*1-8), Followed by Atezo+PBO (Cycle*9 and Beyond)Arm A: Atezo+Bev+CisGem (Cycle*1-8), Followed by Atezo+Bev (Cycle*9 and Beyond)
AnaemiaBlood and lymphatic system disorders51/8137/78
Neutrophil count decreasedInvestigations32/8138/78
NauseaGastrointestinal disorders32/8132/78
ConstipationGastrointestinal disorders23/8130/78
HypertensionVascular disorders15/8129/78
Platelet count decreasedInvestigations22/8122/78
FatigueGeneral disorders18/8121/78
PyrexiaGeneral disorders20/8114/78
NeutropeniaBlood and lymphatic system disorders17/8117/78
Aspartate aminotransferase increasedInvestigations17/8110/78

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Arm B: Atezo+PBO+CisGem (Cycle*1-8), Followed by Atezo+PBO (Cycle*9 and Beyond)Arm A: Atezo+Bev+CisGem (Cycle*1-8), Followed by Atezo+Bev (Cycle*9 and Beyond)Total
Mean63.0 ± 9.859.6 ± 9.961.3 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)Arm B: Atezo+PBO+CisGem (Cycle*1-8), Followed by Atezo+PBO (Cycle*9 and Beyond)Arm A: Atezo+Bev+CisGem (Cycle*1-8), Followed by Atezo+Bev (Cycle*9 and Beyond)Total
Female453075
Male384987
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm B: Atezo+PBO+CisGem (Cycle*1-8), Followed by Atezo+PBO (Cycle*9 and Beyond)Arm A: Atezo+Bev+CisGem (Cycle*1-8), Followed by Atezo+Bev (Cycle*9 and Beyond)Total
Hispanic or Latino112
Not Hispanic or Latino8278160
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm B: Atezo+PBO+CisGem (Cycle*1-8), Followed by Atezo+PBO (Cycle*9 and Beyond)Arm A: Atezo+Bev+CisGem (Cycle*1-8), Followed by Atezo+Bev (Cycle*9 and Beyond)Total
American Indian or Alaska Native000
Asian353772
Native Hawaiian or Other Pacific Islander000
Black or African American112
White464187
More than one race000
Unknown or Not Reported101
08

Study locations

49 sites
  • City of Hope Cancer Center
    Duarte, California 91010, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Duke Cancer Center
    Durham, North Carolina 27710, United States
  • Sarah Cannon Research Institute / Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • University of Virginia
    Charlottesville, Virginia 22903, United States
  • Nanfang Hospital, Southern Medical University
    Guangzhou, 510515, China
  • Sir Run Run Shaw Hospital Zhejiang University
    Hangzhou City, 310016, China
  • Zhongshan Hospital Fudan University
    Shanghai, 200032, China
  • Queen Mary Hospital; Dept. Of Haematology & Oncology
    Hong Kong, Hong Kong
  • Prince of Wales Hosp; Dept. Of Clinical Onc
    Shatin, Hong Kong
  • Fondazione Pascale; U.O. Sperimentazioni Cliniche
    Napoli, Campania 80100, Italy
  • Azienda Ospedaliero Universitaria di Bologna; Istituto di Ematologia "Lorenzo e Ariosto Seragnoli"
    Bologna, Emilia-Romagna 40139, Italy
  • Istituto Clinico Humanitas - Humanitas Cancer Center
    Rozzano, Sicilia 20089, Italy
  • IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II
    Padova, Veneto 35128, Italy
  • CHA Bundang Medical Center
    Gyeonggi-do, 13496, Korea, Republic of
  • Seoul National University Bundang Hospital
    Seongnam-si, 463-707, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • SP ZOZ Wojewódzki Szpital Specjalistyczny nr 4; Oddzial Onkologii Klinicznej
    Bytom, 41-902, Poland
  • Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii
    Gdansk, 80-214, Poland
  • Szpital Wojewódzki im. Miko?aja Kopernika; Oddzia? Dzienny Chemioterapii
    Koszalin, 75-581, Poland
  • NIO im Marii Sklodowskiej-Curie; Klinika Onkologii i Radioterapii
    Warszawa, 02-034, Poland
  • Dolno?l?skie Centrum Onkologii; Oddzia? Onkologii Klinicznej i Chemioterapii
    Wroc?aw, 53-413, Poland
  • FSBI "National Medical Research Center of Oncology N.N. Blokhin?
    Moscow, Moskovskaja Oblast 115478, Russian Federation
  • First Moscow State Medical University n.a. I.M. Sechenov
    Moscow, Moskovskaja Oblast 119991, Russian Federation
  • SBIH "Moscow Clinical Scientific and Practical Center named after A.S. Loginov of DHM"
    Moskva, Moskovskaja Oblast 111123, Russian Federation
  • GBUZ Saint Petersburg Clinical Research Center of Specialized Types of Care (Oncology)
    Saint Petersburg, Sankt Petersburg 197758, Russian Federation
  • Complejo Hospitalario de Navarra; Servicio de Oncologia
    Pamplona, Navarra 31008, Spain
  • Hospital Universitari Vall d'Hebron; Oncology
    Barcelona, 08035, Spain
  • Hospital Ramon y Cajal; Servicio de Oncologia
    Madrid, 28034, Spain
  • Complejo Hospitalario de Orense; Servicio de Oncologia
    Orense, 32005, Spain
  • Hospital Universitario Miguel Servet; Servicio Oncologia
    Zaragoza, 50009, Spain
  • Taipei Veterans General Hospital; Department of Oncology
    Taipei City, 112201, Taiwan
  • National Taiwan Uni Hospital; Dept of Oncology
    Taipei, 100, Taiwan
  • Maharaj Nakorn Chiang Mai Hosp; Oncology Unit
    Chiangmai, 50200, Thailand
  • Srinagarind Hospital; Medical Oncology Unit
    Khon Kaen, 40002, Thailand
  • Sunpasitthiprasong Hospital; Oncology and/or Hematology
    Ubon Ratchathani, 34000, Thailand
  • Adana Ac?badem Hospital Oncology Department
    Adana, 01130, Turkey
  • Memorial Ankara Hastanesi
    Ankara, 06520, Turkey
  • Inonu University Medical Faculty Turgut Ozal Medical Center Medical Oncology Department
    Malatya, 44280, Turkey
  • Koc Universitesi Hastanesi; T?bbi Onkoloji
    Zeyt?nburnu, 34010, Turkey
  • SI Institute of general&urgent surgery n/a Zaytseva V.T NAMSU
    Kharkiv, Kharkiv Governorate 61018, Ukraine
  • ?Kharkov Regional Oncology Center
    Kharkiv, Kharkiv Governorate 61070, Ukraine
  • SI "Shalimov National Institute of Surgery and Transplantation" of Nat.Acad of Med.Sci of Ukraine
    Kyiv, KIEV Governorate 03126, Ukraine
  • Beatson West of Scotland Cancer Centre
    Glasgow, G12 0YN, United Kingdom
  • Royal Free Hospital
    London, NW3 2QS, United Kingdom
  • Churchill Hospital
    Oxford, OX3 7LJ, United Kingdom
  • Royal Marsden Hospital (Sutton)
    Sutton, SM2 5PT, United Kingdom
09

References and documents

Publications

  • Hack SP, Verret W, Mulla S, Liu B, Wang Y, Macarulla T, Ren Z, El-Khoueiry AB, Zhu AX. IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. Ther Adv Med Oncol. 2021 Jul 31;13:17588359211036544. doi: 10.1177/17588359211036544. eCollection 2021. PubMed 34377158 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here ( https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in May 2022, 14 months.

Results were first posted in Jun 2023, 1 year 1 month after primary completion.

Of 129 phase 2 interventional studies under Biliary Tract Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 68. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2020
First posted
Dec 21, 2020
StartActual
Feb 23, 2021
Primary completionActual
May 16, 2022
CompletionActual
Aug 25, 2023
Results first posted
Jun 29, 2023
Last update
Jul 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04677504
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 21, 2020
Start date
Feb 23, 2021
Primary completion
May 16, 2022
Completion
Aug 25, 2023
Results posted
Jun 29, 2023
Last update
Jul 3, 2024

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bevacizumab

Start the discussion